rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings indicate that adenomas might be less important in the cancer development in the group of families with BRAF-V600E mutations and indirectly support a previous hypothesis that tumors might develop through the hyperplastic polyp-serrated adenoma pathway.
|
17119056 |
2006 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Papillary thyroid cancer subjects harboring RET/PTC rearrangements developed this cancer earlier than did cases with BRAF(V600E) mutation (P = 0.03).
|
18757433 |
2008 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The usefulness of immunohistochemistry (IHC) as a new approach for the detection of BRAF V600E in cancer patients has been recently reported.
|
23927882 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We calculated and compared the diagnostic performances of cytology and cytology with BRAF(V600E) mutation analysis to detect malignancy among thyroid nodules according to ultrasound features and size.
|
23717622 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF-V600E (1799T > A) is one of the most frequently reported driver mutations in multiple types of cancers, and patients with such mutations could benefit from selectively inactivating the mutant allele.
|
28918044 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, we show that SkE, a very potent inhibitor of B-Raf-V600E, is highly effective against cancer cell lines that exhibit constitutive activation of the ERK1/2 pathway.
|
23518796 |
2012 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Right-sided colon tumors more frequently have BRAF (p.V600E) mutations and have higher methylation grades when compared to left-sided malignancies.
|
24244575 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E Mutation in Multiple Primary Malignancies: A Hairy Affair.
|
30680261 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aims of this study were to evaluate the utility of US-guided FNAB in the diagnostic assessment of nodules with or without clinical/US features suggestive for malignancy and to investigate the additional contribution of BRAF V600E mutation analysis in the detection of differentiated thyroid cancer.
|
22535974 |
2012 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recent developments in v-raf murine sarcoma viral oncogene homolog B1 (BRAF)(V600E)-specific small molecule inhibitors and their clinical approval for other cancer types could turn BRAF(V600E) into a promising molecular predictor of outcome in pilocytic astrocytomas, given a treatment with a mutation-specific BRAF inhibitor is applied.
|
23160425 |
2012 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.
|
29422527 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The mutation BRAF V600E is thought to be a putative prognostic marker of the aggressiveness of several cancers among which is also papillary thyroid cancer.
|
23925579 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Since the V600E BRAF protein has emerged as an important therapeutic target for cancer, the developed assay should facilitate future BRAF-related basic and clinical studies.
|
27497007 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The recognition of this functional trilogy provides insight on how BRAF(V600E) determines cancer initiation, progression, and invasiveness in PTC, also identifying new therapeutic targets for the treatment of highly aggressive forms.
|
21903858 |
2011 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Approximately 75% of the cases were cytologically diagnosed as being positive for malignancy and these cases were associated with both the classic and tall cell variants of PTC at the time of resection, a greater likelihood of extrathyroidal extension, and the V600E type of BRAF mutation.
|
22887810 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of BRAF(V600E) mutation had limited value in diagnoses of malignancy in follicular neoplasms but can ascertain malignancy in subset of suspicious for malignancy FNABs.
|
21948220 |
2011 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors the oncogenic T1799A BRAF mutation.
|
19883729 |
2010 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Cytomorphologic features can help select nodules for the BRAF(V600E) mutation test among nodules read as "suspicious for malignancy" on cytology.
|
26187369 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Reverse Phase Proteomic Array (RPPA, MD Anderson Cell Lines Project), RNAseq (Cancer Cell Line Encyclopedia) and vemurafenib sensitivity (Cancer Therapeutic Response Portal) data for BRAF-V600E cancer cell lines were curated.
|
31672130 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation was associated with an advanced stage of cancer (P = .045) and was found to be associated with poor prognostic factors.
|
23690118 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In FNA biopsy samples (n=186), immunocytochemical expression of caveolin-1 and BRAF V600E mutation coincided with malignancy.
|
27818286 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We performed a literature review of five commonly requested off-label IHC predictive biomarkers in gastrointestinal tract (GIT) malignancies: HER2, mismatch repair (MMR), PD-L1, BRAF V600E and ROS1.
|
31221175 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PGC1α-negative papillary cancer was associated with BRAF V600E mutation, large tumor size, extrathyroidal or lymphovascular invasion, lymph node metastasis, and advanced stage.
|
31333799 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Besides confirming the constant presence of BRAF-V600E in all patients with hairy cell leukemia, we observed ubiquitous phospho-ERK expression in this malignancy.
|
23349307 |
2013 |